Journals / Pamukkale Tıp Dergisi / 2010 / Cilt: 3 - Sayı: 3

Beyin tümörü prognozunda PIK3CA, RUNX3, COX-2 ve DMBT1 genlerinin ekspresyon profi lleri: ön çalışma

Expression profi les of PIK3CA, RUNX3, COX-2 and DMBT1 genes in brain tumor prognosis: a preliminary study

Pages
109–114
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Suppression of DMBT1 and RUNX3 is associated with decreased survive, however no signifi cant difference was determined between expressions of PIK3CA, DMBT1 and RUNX3 genes and overall survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The two main subgroups of the important genes functioning in the development of cancer including brain tumors are tumor suppressor genes and oncogenes.
📊
Key Findings & Data:The aim of this pilot study was to determine the expression profi les of tumor suppressor genes; RUNX3 (Runt-related transcription factor 3), DMBT1 (deleted in malignant brain tumors 1), and oncogenes PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) and COX–2 (Cyclooxygenase-2) in brain tumors.
💡
Conclusion & Impact:Suppression of DMBT1 and RUNX3 is associated with decreased survive, however no signifi cant difference was determined between expressions of PIK3CA, DMBT1 and RUNX3 genes and overall survival.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The two main subgroups of the important genes functioning in the development of cancer including brain tumors are tumor suppressor genes and oncogenes. The aim of this pilot study was to determine the expression profi les of tumor suppressor genes; RUNX3 (Runt-related transcription factor 3), DMBT1 (deleted in malignant brain tumors 1), and oncogenes PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) and COX–2 (Cyclooxygenase-2) in brain tumors. Explant cell cultures were performed using brain tumor tissues from the 14 cases. Total RNA was isolated from the cultured cells. Relative ratio of expression profi les of the tumor suppressor genes and oncogenes were determined by using real-time online RT-PCR. U-87MG cell line was used as positive control. The mean relative ratios of DMBT1, RUNX3, COX-2 and PIK3CA genes were found; 72.2, 59.3, 0.119 and 48.5; respectively. COX-2 over-expression correlated with a signifi cantly reduced survival (Log- Rank, p= 0.049). Suppression of DMBT1 and RUNX3 is associated with decreased survive, however no signifi cant difference was determined between expressions of PIK3CA, DMBT1 and RUNX3 genes and overall survival. High COX-2 expression is found to be associated with clinically more aggressive brain tumors. Our preliminary data suggests that COX-2 gene may be used as a therapeutic target.

Özet

Beyin tümörleri de dahil olmak üzere kanser gelişiminde önemli rol oynayan genlerin iki ana alt grubu onkogenler ve tümör baskılayıcı genlerdir. Bu ön çalışmanın amacı, tümör baskılayıcı genlerden RUNX3 (Runt-relatedtranscription factor 3), DMBT1 (Deleted in Malignant Brain Tumors 1) ve onkogenlerden PIK3CA (Fosfoinosid- 3-kinaz, katalitik, alfa polipeptid), COX–2 (Siklooksigenaz-2) genlerinin beyin tümörlerinde ifade düzeyini saptamaktır. On dört olgunun beyin tümörü dokularından hücre kültürü ortamında çoğalması sağlandı. Kültüre edilmiş hücrelerden total RNA’lar izole edildi. Gerçek zamanlı RT-PCR metodu kullanılarak onkogen ve tümör baskılayıcı genlerin ekspresyon profi llerinin bağıl oranları saptandı. U87MG hücre hattı pozitif kontrol olarak kullanıldı. DMBT1, RUNX3, COX-2 ve PIK3CA genlerinin bağıl oranları ortalaması sırasıyla 72.2, 59.3, 0.119 ve 48.5 bulundu. COX-2 aşırı ekspresyonu, anlamlı olarak azalmış sağkalım ile korelasyon gösterdi (Log-Rank,p= 0.049). DMBT1 ve RUNX3 genlerinin baskılanması azalmış sağkalımla ilişkili olduğu saptandı ancak PIK3CA, DMBT1 ve RUNX3 ekspresyonları arasında ve sağkalım üzerinde anlamlı bir farklılık saptanmadı. Yüksek COX-2 ekspresyonu klinik olarak fazla agresif beyin tümörleri ile ilişkili olduğu gösterildi. Elde ettiğimiz ön deney sonuçlarımız, COX-2 geninin terapötik hedef olarak kullanılabilir olabileceğini önermektedir.

🔖

Cite This Article

SÜSLÜER, S. Y., AVCI, Ç. B., DOĞAN, Z. Ö. Ş., DODURGA, Y., OKTAR, N., NUMANOĞLU, S., DALBASTI, T., AKALIN, T., GÜNDÜZ, C. (2010). Beyin tümörü prognozunda PIK3CA, RUNX3, COX-2 ve DMBT1 genlerinin ekspresyon profi lleri: ön çalışma. Pamukkale Tıp Dergisi, Cilt: 3 - Sayı: 3, 109–114. https://ajindex.com/articles/286353

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Sathornsumetee S, Rich JN. New approaches to primary brain tumor treatment. Anticancer Drugs 2006; 17: 1003-16
  2. Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 839-45
  3. Sanson M, Thillet J, Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol 2004; 16: 607-13
  4. Hill JR, Kuriyama N, Kuriyama H, Israel MA. Molecular genetics of brain tumors. Arch Neurol 1999; 56: 439-41
  5. Hasegawa K, Yazumi S, Wada M et al. Restoration of RUNX3 enhances transforming growth factor-betadependent p21 expression in a biliary tract cancer cell line. Cancer Sci 2007; 98: 838-43
  6. Wada M, Yazumi S, Takaishi S et al. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 2004; 23: 2401-7
  7. Kang W, Nielsen O, Fenger C, Leslie G, Holmskov U, Reid KB. Induction of DMBT1 expression by reduced ERK activity during a gastric mucosa differentiationlike process and its association with human gastric cancer. Carcinogenesis 2005; 26: 1129-37
  8. Pang JC, Dong Z, Zhang R et al. Mutation analysis of DMBT1 in glioblastoma, medulloblastoma and oligodendroglial tumors. Int J Cancer 2003; 105: 76-8
  9. Sasaki M, Huang SF, Chen MF et al. Decrease of deleted in malignant brain tumour-1 (DMBT-1) expression is a crucial late event in intrahepatic cholangiocarcinoma. Histopathology 2003; 43: 340-6
  10. Wu W, Kemp BL, Proctor ML et al. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res 1999; 59: 1846-51
  11. Hara A, Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic signifi cance. Acta Neuropathol 2004; 108: 43-8
  12. Shono T, Tofi lon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic signifi cance and molecular correlations. Cancer Res 2001; 61: 4375-81
  13. Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogenactivated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 2007; 67: 6121-9
  14. Sminia P, Stoter TR, Van der Valk P et al. Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme. J Cancer Res Clin Oncol 2005; 131: 653-61
  15. Broderick DK, Di C, Parrett TJ et al. Mutatio